This will work for only very limited populations such as in the legal system who are required to take meds as part of their parole and such. Putting an electronic tracking device in a patient with paranoia is not going to help a patient and I'd venture to say, may even increase paranoid delusions. Another area it might make sense is research to assure the study participants are taking medications as prescribed to assure accurate data endpoint results. Opioids would make sense to track too- although there'd be ways to work around the system such as taking the external tracking device off when taking extra doses. Overall, truly limited use and Otsuka is marketing it as such
Does a tree make a sound when it falls in a forest if no one is around to hear it? Much ado about nothing. No one in the world bothered to comment on the press release other than you and now me.
When you spend other people's money then everything is a good idea. The only winner here is Proteus, They took Otsuka shareholders to the cleaners and then some.
